Analysts Offer Insights on Healthcare Companies: Tonix Pharma (NASDAQ: TNXP) and Aptose Biosciences (NASDAQ: APTO)

By Austin Angelo

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Tonix Pharma (NASDAQ: TNXP) and Aptose Biosciences (NASDAQ: APTO).

Tonix Pharma (NASDAQ: TNXP)

In a report released today, Scott Henry from Roth Capital reiterated a Hold rating on Tonix Pharma (NASDAQ: TNXP), with a price target of $0.60. The company’s shares opened today at $0.42, close to its 52-week low of $0.40.

According to TipRanks.com, Henry is a 1-star analyst with an average return of -1.5% and a 38.6% success rate. Henry covers the Healthcare sector, focusing on stocks such as Acerus Pharmaceuticals Corporation, Flamel Technologies S.A., and Apricus Biosciences Inc.

Currently, the analyst consensus on Tonix Pharma is Hold and the average price target is $1, representing a 139.3% upside.

In a report issued on November 10, Oppenheimer also reiterated a Hold rating on the stock.
Aptose Biosciences (NASDAQ: APTO)

Roth Capital analyst Joseph Pantginis reiterated a Buy rating on Aptose Biosciences (NASDAQ: APTO) today and set a price target of $8. The company’s shares opened today at $0.93, close to its 52-week low of $0.83.

Pantginis noted:

“We believe the anticipated re-start of the study as well as the growing visibility for newly licensed CG-806 should drive the shares. Reiterate Buy/$8 target. Event Aptose announced 3Q16 results, posting EPS of (C$0.31) compared with our estimate of (C$0.47) and consensus of (C$0.32).”

According to TipRanks.com, Pantginis is ranked 0 out of 5 stars with an average return of -10.8% and a 38.4% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals, Inc., Applied Genetic Technologies, and ImmunoCellular Therapeutics.

Aptose Biosciences has an analyst consensus of Moderate Buy.